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Introduction {#sec1}
============

Pluripotency denotes a flexible cellular potential to differentiate into all lineages of the developing embryo. In mammals this property emerges in the epiblast of the pre-implantation blastocyst ([@bib5], [@bib18], [@bib50]). After implantation, epiblast cells remain pluripotent while undergoing profound cellular and molecular changes in preparation for gastrulation ([@bib52]). In mice the post-implantation epiblast develops into a cup-shaped epithelium, the egg cylinder. Signaling cues from extra-embryonic tissues then pattern the egg cylinder to establish anterior-posterior and proximal-distal axes prior to lineage specification (reviewed in [@bib1], [@bib51]).

In mouse the naive phase of pluripotency can be captured in culture in the form of embryonic stem cells (ESCs) (reviewed by [@bib43]). Dual inhibition (2i) of MEK1/2 and glycogen synthase kinase 3 (GSK3) ([@bib64]), optionally in combination with the cytokine leukemia inhibitory factor (LIF), allows mouse ESCs to maintain the transcription profile, DNA hypomethylation status, and developmental potential characteristic of the pre-implantation epiblast from which they are derived ([@bib5], [@bib6], [@bib20], [@bib29]). ESCs in 2i are stable and relatively homogeneous, a condition referred to as "ground state" ([@bib34], [@bib58]). Such uniformity in defined conditions provides an experimental system to characterize cellular and molecular events that generate multiple lineage-committed states from a developmental blank canvas.

ESC progression from the ground state is initiated simply by removal of the inhibitors. In adherent culture this results predominantly in neural specification ([@bib63]) or in a mixture of neural and mesoendodermal fates, depending on cell density ([@bib24]). Previous studies have identified expression of REX1 (gene name *Zfp42*) as a marker of undifferentiated ESCs that is downregulated prior to lineage specification ([@bib4], [@bib24], [@bib23], [@bib28], [@bib55], [@bib58], [@bib59], [@bib61]). In this study, we exploit a *Rex1*::*GFPd2* (RGd2) reporter cell line ([@bib24]) to isolate cells at initial stages of progression from naive pluripotency following release from 2i in adherent serum-free culture. We examine whether cells exiting the ESC state guided by autocrine cues commit preferentially to a neural fate or exhibit competence for multi-lineage differentiation.

Results {#sec2}
=======

Multi-lineage Differentiation Capacity Is Manifest after Loss of Naive ESC Identity {#sec2.1}
-----------------------------------------------------------------------------------

In *Rex1*::*GFPd2* (RGd2) reporter ESCs, a short-half-life GFP is expressed from the endogenous REX1 (*Zfp42*) locus ([@bib34], [@bib59]). Loss of the reporter coincides with downregulation of naive pluripotency factors and functionally with extinction of clonal self-renewal capacity ([@bib24]) ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). GFP downregulation is asynchronous across the population. For at least 16 hr cells remain uniformly GFP high, but by 24 hr expression is heterogeneous and in a minority of cells the reporter has been downregulated ([@bib24]). Rex1-low cells have lost the capacity to resume self-renewal in 2i/LIF, whereas cells with high GFP produce undifferentiated ESC colonies with the same efficiency as cells in the initial 2i culture ([Figure S1](#mmc1){ref-type="supplementary-material"}D, see also [@bib24]). We focused attention on the character of cells 24 hr after 2i withdrawal, the first time point at which it is practical to isolate a substantial population of Rex1-low cells by flow cytometry ([@bib24]).

We first investigated capacity to form primordial germ cell (PGC)-like cells (PGCLCs). Previous studies have shown that undifferentiated ESCs are not directly competent for germline specification but must first transition to a transient epiblast-like (EpiLC) population which can then be induced to form PGCLCs ([@bib21], [@bib42]). The EpiLC population is obtained by transfer from 2i/LIF to N2B27 medium supplemented with activin A, basic fibroblast growth factor (FGF), and the serum substitute KSR (Knockout Serum Replacement) for 48 hr ([@bib21]). We assessed whether the first cells that exit the ground state in N2B27 alone exhibit competence to form PGCLCs. For this purpose we used RGd2 ESCs transfected with a doxycycline (Dox)-regulatable expression construct containing the three germline determination factors *Prdm1* (BLIMP1), *Prdm14*, and *Tfap2c* ([@bib32], [@bib42]). Stable transfectants were withdrawn from 2i for 24 hr and the high and low GFP fractions isolated by fluorescence-activated cell sorting (FACS) ([Figure 1](#fig1){ref-type="fig"}A). Sorted cells (2,500) were aggregated with or without Dox in non-adherent 96-well plates in medium containing 15% KSR ([@bib42]). After 4 days, the expression of OCT4 and BLIMP1 protein was analyzed. Dual expression of BLIMP1 and OCT4 is a combination unique to PGCs and PGCLCs ([@bib21], [@bib26], [@bib42]). Furthermore, undifferentiated ESCs do not tolerate appreciable levels of BLIMP1 protein ([@bib33]). In the absence of Dox, few cells co-expressing BLIMP1 with OCT4 were present in aggregates from either population ([Figure 1](#fig1){ref-type="fig"}B). Dox treatment induced double-positive cells from the Rex1-low fraction but had little effect on the Rex1-high cells ([Figures 1](#fig1){ref-type="fig"}B and 1C). Quantitative imaging analysis confirmed a higher number of cells were double-positive for OCT4 and BLIMP1 in cultures derived from Rex1-low cells ([Figure 1](#fig1){ref-type="fig"}D), at a frequency comparable with that previously reported for EpiLCs ([@bib42]). By qRT-PCR analysis we detected upregulated expression of endogenous *Prdm1* (BLIMP1), along with *Prdm14*, *Tfap2c*, *Nanos3*, and *Stella*, as well as maintenance of *Pou5f1* (OCT4) ([Figure 1](#fig1){ref-type="fig"}E). *T* (BRACHYURY) was induced transiently on day 2 as previously described for PGCLC induction ([Figure 1](#fig1){ref-type="fig"}E) ([@bib42]). We also carried out cytokine induction of PGCLCs and observed earlier upregulation of PGC markers *Nanos3*, *Tfap2c*, and *Stella* in Rex1-low cells compared with Rex1-high cells ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The kinetics of upregulation and overall expression levels of PGC markers were comparable with those for EpiLC treated in parallel ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Thus, ESCs newly exited from the ground state under autocrine stimulation in defined conditions have acquired competence for germline specification.Figure 1Acquisition of PGCLC Differentiation Capacity(A) Experimental setup for transcription factor-dependent PGCLC specification.(B) Expression of BLIMP1 and OCT4 in day-4 aggregates differentiated in the presence or absence of Dox to induce transcription factor overexpression. Scale bar, 60 μm.(C) Zoom-in of the expression of BLIMP1 and OCT4 in day-4 aggregates differentiated in the presence or absence of Dox to induce transcription factor overexpression. Asterisks indicate overexpression staining artifacts. Scale bar, 20 μm.(D) Quantification of the percentage of cells expressing BLIMP1, OCT4, and both markers in aggregates cultured with Dox and stained on day 4.(E) qRT-PCR of endogenous PGC-associated transcripts.Data in (D) and (E) from three independent experiments, mean and SD shown. ^∗^p \< 0.01, ^∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We then examined somatic lineage potential of Rex1-low cells. Sorted fractions were plated in media that favor mesoderm, definitive endoderm, or neural lineages, respectively, and the timing and efficiency of differentiation quantified.

Activin A combined with GSK3 inhibition (GSK3(i)) elicits the upregulation of primitive-streak markers such as BRACHYURY (*T*) in differentiating ESCs ([@bib17], [@bib40], [@bib56], [@bib57]). We modified RGd2 cells to express an mKO2 fluorescent reporter from the *T* locus ([Figure 2](#fig2){ref-type="fig"}A). *T*::*mKO2* was not expressed in undifferentiated ESCs in 2i ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and not detected until day 3 of treatment with activin A plus GSK3(i). In contrast, Rex1-low cells replated in the presence of activin A and GSK3(i) upregulated *T*::*mKO2* after 1 day and all cells were positive by day 2. Rex1-high cells upregulated *T*::*mKO2* more slowly and some cells remained GFP high even after 3 days, indicating they remained undifferentiated and unresponsive to differentiation cues ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Multi-lineage Differentiation Capacity Is Manifest in Rex1-Low Cells(A and B) Experimental set up and sample analysis for activin A + GSK3(i) treatment (A). Histogram shows the percentages of cells expressing *T*:*mKO2* or RGd2 (B).(C) Experimental setup and sample analysis for lateral mesoderm differentiation. Histogram showing the percentage of FLK1^+^/E-CAD^−^ cells.(D) Experimental setup and sample analysis for definitive endoderm differentiation.(E) Percentage of CXCR4^+^/E-CADH^+^ double-positive cells.(F) Normalized number of cells during definitive endoderm differentiation. The number of cells was normalized to the highest value obtained in that individual experiment.(G) Single-cell analysis during definitive endoderm differentiation by seeding fluorescently labeled Rex1-Pos or Rex1-Neg cells at clonal density among unlabeled cells.(H) Number of clones after 4 days of differentiation.(I) Distribution of the number of cells per clone.(J) Distribution of the percentage of SOX17-positive cells per clone.(K) Experimental setup and sample analysis for neural differentiation. Histogram on the right shows the percentage of SOX1-positive cells during the differentiation time course.Data from three independent experiments, mean and SD shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To test further differentiation, we plated the sorted fractions in conditions that promote lateral mesoderm ([@bib44], [@bib60]). All populations gave rise to FLK1-positive/E-CADHERIN-negative cells after 4--5 days ([Figure 2](#fig2){ref-type="fig"}C).

We assessed definitive endoderm differentiation after sorting by measuring the percentage of CXCR4/E-CADHERIN double-positive cells ([@bib39], [@bib62]) under specific inductive conditions ([@bib40]) ([Figure 2](#fig2){ref-type="fig"}D). Compared with 2i cells or the Rex1-high population, fewer double-positive cells accumulated from the Rex1-low cells ([Figure 2](#fig2){ref-type="fig"}E). However, we noted that the majority of Rex1-low cells died after replating in these conditions ([Figure 2](#fig2){ref-type="fig"}F). The survivors formed SOX17/FOXA2 double-positive cells, and every SOX17-positive cell was positive for FOXA2, substantiating endoderm identity ([@bib9]) ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Induction of the later marker, SOX17, was reduced from Rex1-low cells compared with Rex1-high or 2i cells. We hypothesized that sorted Rex1-low cells might have impaired survival and differentiation because of a requirement for high cell density in the endoderm program. We therefore combined sorted cells with unsorted populations to reproduce the density of non-manipulated cultures ([Figure 2](#fig2){ref-type="fig"}G). To trace the sorted cell progeny, we employed RGd2 cells constitutively labeled with mKO2 under the control of a CAG promoter ([@bib45]). Two hundred sorted labeled cells were plated together with 5.8 × 10^3^ parental cells per 3.8 cm^2^ dish. Cells were exposed to definitive endoderm differentiation medium, then fixed and stained for SOX17 at day 4 ([Figure S2](#mmc1){ref-type="supplementary-material"}D). The total number of mKO2-positive clones was determined, along with the number of SOX17-positive cells per clone and the clone sizes. Similar numbers of clones and sizes were obtained from Rex1-high and -low cells ([Figures 2](#fig2){ref-type="fig"}H and 2I). The majority of Rex1-low cells were able to produce colonies containing SOX17-positive cells, although the output was less than from Rex1-high clones ([Figure 2](#fig2){ref-type="fig"}J).

Finally, we examined cell fate acquisition in N2B27 alone, which is permissive for neural differentiation ([@bib63]). The great majority (≥80%) of cells from both Rex1 fractions became immunopositive for SOX1, an exclusive marker of neuroectoderm ([@bib48], [@bib65]) ([Figure 2](#fig2){ref-type="fig"}K). However, Rex1-low cells showed early upregulation of SOX1, with most cells becoming SOX1 positive on day 2, a day before the Rex1-high population ([Figures 2](#fig2){ref-type="fig"}K and [S2](#mmc1){ref-type="supplementary-material"}E). In these conditions, cell viability and expansion were not significantly different between the populations ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Rex1-low cells subsequently also showed accelerated onset of expression of the neuronal marker type III **β-**TUBULIN ([@bib27]) ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

Overall, these data indicate that after 24 hr of monolayer culture guided by autocrine cues, Rex1-low cells are competent for multi-lineage specification and respond more rapidly to induction than either ground-state ESCs or Rex1-high cells.

NODAL Does Not Regulate Kinetics of Exit from the Naive State {#sec2.2}
-------------------------------------------------------------

FGF4 is an autocrine factor that drives ESC transition via ERK signaling upon release from 2i ([@bib4], [@bib25], [@bib28], [@bib53]). A second potential autocrine regulator is NODAL ([@bib16], [@bib41], [@bib47]). Detection of SMAD2 phosphorylation indicates that the pathway is active in ground-state ESCs, attributable to autocrine expression of NODAL ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Treatment with the ALK5/4/7 receptor inhibitor A83-01 (Alk(i)) ([@bib54]) eliminated SMAD2 phosphorylation after 30 min ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, Alk(i) did not affect colony-forming capacity in 2i/LIF, even after continuous culture for three passages ([Figure S3](#mmc1){ref-type="supplementary-material"}B), confirming that the NODAL pathway is not needed for maintenance of ground-state mouse ESCs.

We examined the contribution of autocrine NODAL pathway signaling in progression from the ESC state. We analyzed changes in gene expression in cells withdrawn from 2i in the continuous presence of Alk(i) ([Figure 3](#fig3){ref-type="fig"}A) and found no difference in the dynamics of downregulation of *Nanog* or *Klf2* mRNA ([Figure 3](#fig3){ref-type="fig"}B), nor of NANOG and KLF4 protein ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). Functionally, the rate of decay in ESC clonogenicity was also unaffected ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Inhibition of Endogenous NODAL Signaling Does Not Affect Exit from the Naive State(A) Experimental setup.(B) Relative expression of pluripotency factors *Klf2* and *Nanog* over time when cells are differentiated in control (DMSO) or Alk(i).(C) Percentage of KLF4- and NANOG-positive cells over time after 2i withdrawal when cells are differentiated in the presence or absence of Alk(i).(D) Self-renewal capacity declines at a comparable rate for cells treated with vehicle control or Alk(i).(E) Relative expression of post-implantation markers *Fgf5* and *Otx2* shows faster earlier downregulated for cells treated with Alk(i) over controls.(F) Relative expression of neural-associated genes *Sox1*, *Zic1* and *Pou3f3* over time when cells are differentiated in controls or Alk(i).(G) Inhibition of NODAL signaling results in accelerated reduction of OCT4 protein and increase in SOX1 protein at day 3 of differentiation. Scale bar, 50 μm.Data from three independent experiments, mean and SD shown. ^∗^p \< 0.01. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We evaluated expression of genes associated with the early post-implantation epiblast. Initial upregulation of *Fgf5* and *Otx2* was marginally reduced when NODAL signaling was inhibited ([Figure 3](#fig3){ref-type="fig"}E). However, these genes were subsequently downregulated more acutely on days 3 and 4 ([Figure 3](#fig3){ref-type="fig"}E). Conversely, transcripts for neuroectodermal lineage factors *Sox1*, *Zic1*, and *Pou3f3* were strongly upregulated in day-3/-4 Alk(i)-treated cultures, before appreciable expression in vehicle-treated cells ([Figure 3](#fig3){ref-type="fig"}F). At the protein level, most cells in Alk(i)-treated cultures had downregulated OCT4 and were SOX1 positive after 3 days, indicative of neural commitment, whereas control cultures at this time point displayed a mosaic pattern of co-exclusive SOX1 and OCT4 immunostaining ([@bib30]) ([Figure 3](#fig3){ref-type="fig"}G).

To validate findings with the inhibitor, we deployed small interfering RNAs (siRNAs) against NODAL signaling pathway components. In *Nodal*, *Smad2*/*3*, and *Tdgf1* knockdown experiments, the emergence of OCT4^−^/SOX2^+^ and SOX2^+^/SOX1^+^ cells was accelerated ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). We conclude that suppression of NODAL signaling does not substantially affect initial exit from the naive state but promotes subsequent specification to the neural lineage.

NODAL Signaling Potentiates Multi-lineage Differentiation {#sec2.3}
---------------------------------------------------------

Interrogation of RNA-sequencing data from RGd2 sorted cells ([@bib24]) revealed that NODAL pathway ligands, receptors, intracellular mediators, and target genes are expressed in undifferentiated ESCs and in 24-hr Rex1-high cells. Rex1-low cells, on the other hand, display reduced levels of *Nodal* and *Gdf3* transcripts and decreases in expression of the convertase *Pcsk6* (Pace4), as well as of pathway targets *Lefty1*, *Lefty2*, and *Smad6* ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This prompted treatment with Alk(i) only after sorting ([Figure 4](#fig4){ref-type="fig"}). We found that the Rex1-high population still responded by accelerated upregulation of SOX1 but the Rex1-low fraction showed no change, consistent with the pathway already being downregulated. These observations may explain why exogenous activin A is required to drive mesoendodermal lineage specification.Figure 4NODAL Signaling Acts during the Transition from the Naive StateInhibition of Nodal signaling with Alki(i) in Rex1-high and Rex1-low sorted fractions. Graphs show percentages of SOX1-positive cells after sorting and replating in the presence or absence of Alk(i). Data from three independent experiments, mean and SD shown. ^∗^p \< 0.05.

In light of these results, we postulated that NODAL signaling may function during the primary transition from naive pluripotency. We therefore inhibited the pathway for only the first 24 hr and analyzed the resulting Rex1-low cells. In line with results for continuous treatment, exposure to Alk(i) for 24 hr had little effect on downregulation of RGd2 ([Figure S4](#mmc1){ref-type="supplementary-material"}B) or other naive pluripotency factor transcripts ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Upregulation of early post-implantation markers was also similar to that in vehicle-treated cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). One day after sorting and replating, SOX1 protein was detectable only in a minority of untreated cells ([Figure 5](#fig5){ref-type="fig"}A). In contrast, up to half of cells generated after Alk(i) treatment upregulated SOX1 protein on day 1. Cell numbers appeared reduced at all time points for inhibitor-treated samples, although the difference was not statistically significant ([Figure 5](#fig5){ref-type="fig"}B).Figure 5NODAL Signaling during Exit from the Naive State Prevents Precocious Neuralization(A) Percentage of SOX1-positive cells arising from Rex1-low cells following control or Alk(i) treatment.(B) Number of cells over the period analyzed in (A).(C) Activin A/GSK3(i) induction of Alk(i) or control treated Rex1-low cells. Numbers of *T*::*mKO2-*positive cells, along with total cell numbers.(D) To determine the normalized number of cells as a percentage for each independent experiment, we normalized the number of cells by the highest value obtained in that independent experiment.(E) Experimental setup of definitive endoderm clonal assay.(F) Distribution of the percentage of SOX17-positive cells per clone.(G) Distribution of the number of cells per clone.(H) Experimental setup of transcription factor-dependent PGCLC differentiation. Images show day-4 cultures in the presence of Dox from Alk(i)-treated and control cells. Scale bar, 1 mm.(I) qRT-PCR assay of PGC-associated genes during induction process.Data from three independent experiments, mean and SD shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We examined whether faster neural specification as a consequence of Alk(i) pre-treatment has consequences for other lineages. We analyzed the response of Alk(i)-treated cells to activin A/GSK3(i). Rex1-low cells showed a major reduction in the number of *T*::*mKO2*-positive cells ([Figure 5](#fig5){ref-type="fig"}C). Interestingly, this was mainly attributable to reduced total cell numbers after exposure to activin A/GSK3(i) ([Figures 5](#fig5){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}D). A similar reduction in cell survival/proliferation was observed in cells exposed to lateral mesoderm differentiation conditions ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G). Thus, Rex1-low cells emerging after Alk(i) treatment appear to be compromised in their ability to respond to mesoderm-inducing signals. To evaluate endodermal specification, we employed the clonal mixing protocol described previously ([Figure 5](#fig5){ref-type="fig"}E). The total number of clones was not reduced ([Figure S4](#mmc1){ref-type="supplementary-material"}H), but we observed a shift to smaller clones ([Figure 5](#fig5){ref-type="fig"}F) with fewer SOX17-positive cells ([Figure 5](#fig5){ref-type="fig"}G).

We assessed whether prior treatment with Alk(i) for 24 hr affected the potential of Rex1-low cells to respond to PGC-inducing transcription factors ([Figure 5](#fig5){ref-type="fig"}H). Alk(i)-treated cells produced less compact and smaller aggregates than control cultures ([Figure 5](#fig5){ref-type="fig"}H). The gene expression profile at days 2 and 4 of culture showed lower upregulation of endogenous *Prdm14*, *Nanos3*, and *Stella*, indicating significantly impaired PGCLC induction ([Figure 5](#fig5){ref-type="fig"}I). We similarly observed lower upregulation of endogenous *Nanos3*, *Tfap2c*, and *Stella* upon cytokine induction of PGCLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}I).

Collectively these findings indicate that suppression of NODAL signaling during exit from the ESC state reduces the capacity of cells to respond productively to inductive cues for mesoderm, endoderm, and germ cell specification.

*Nodal* Gene Deletion Compromises Germline and Somatic Lineage Specification {#sec2.4}
----------------------------------------------------------------------------

To confirm that the effect of Alk inhibitor treatment was indeed attributable to the absence of NODAL stimulation, we genetically inactivated *Nodal*. We employed CRISPR/Cas9 and used a pair of guide RNAs targeting the second and third exons ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Two clones negative for *Nodal* mRNA were identified and used for subsequent analyses ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Consistent with the inhibitor experiments, we observed no changes in the clonogenic capacity of *Nodal*-deficient ESCs in 2i/LIF ([Figure 6](#fig6){ref-type="fig"}A). The expression of key pluripotency or early post-implantation genes was also unaffected ([Figure 6](#fig6){ref-type="fig"}B). Expression of *Lefty1*, a NODAL target gene, was reduced to almost undetectable levels in the knockout clones but could be restored by addition of activin A to the culture medium ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Deletion of *Nodal* Impairs Germline and Somatic Lineage Competence(A) Colony-forming assay on wild-type (WT) and *Nodal*-mutant (KO) ESCs in 2i/LIF.(B) Heatmap of marker expression determined by qRT-PCR in *Nodal* KO cells in 2i and in the presence of 5 ng/mL activin A. n.d., not detected.(C) Differentiation scheme for *Nodal* KO clones in inductive conditions for PGCLCs.(D) Aggregate morphology on day 4 of PGCLC induction. Scale bar, 1 mm.(E) qRT-PCR assay for PGC-associated genes during PGCLC induction.(F) Experimental setup for neural differentiation. Number of SOX1-positive cells is shown.(G) Activin A/GSK3(i) induction on WT and KO clones. Number of BRACHYURY-positive cells is shown.Two independent *Nodal* KO clones from three independent experiments, mean and SD shown. ^∗^p \< 0.01, ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.0001 in pairwise comparison of WT and KO. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

We examined the lineage propensity of 24-hr Rex1-low cells from *Nodal*-mutant cells. During cytokine induction of PGCLCs, mutant aggregates were less compact ([Figure 6](#fig6){ref-type="fig"}C) and the expression of PGC markers was significantly reduced. *Nodal* KO cells also displayed a marked reduction in generation of both SOX1- and BRACHYURY-positive cells in respective inductive culture conditions ([Figures 6](#fig6){ref-type="fig"}E and 6F). In either condition, fewer mutant cells survived compared with wild-type controls or activin A-treated mutant cells. The expression of *Gdf3* ([Figure 6](#fig6){ref-type="fig"}B), a *Vg-1* homolog that may elicit Nodal-like responses ([@bib11]), might partly compensate for the absence of NODAL to enable residual lineage specification. Nonetheless, our results indicate that autocrine NODAL signaling during transition from naive pluripotency facilitates acquisition of multi-lineage competence.

Discussion {#sec3}
==========

The defined context of ground-state ESC culture provides opportunities for experimentally dissecting the interplay between intrinsic and extrinsic factors that mediate progression through pluripotency. Here we investigated the trajectory of ESCs released from the ground state with minimal extrinsic input. We isolated cells that have lost ESC identity within 24 hr based on downregulation of RGd2, corroborated functionally by extinction of self-renewal capability ([@bib24]). These cells show gene expression features related to the peri-implantation epiblast ([@bib24]). Capacitation for germline and somatic lineage specification may be acquired around this formative period ([@bib21], [@bib52]). Indeed newly formed Rex1-low cells readily differentiated into the germline and somatic lineages. Furthermore, we found that endogenous NODAL signaling is crucial for robust multi-lineage competence of cells transitioning out of naive pluripotency.

Rex1-low cells show more rapid upregulation of lineage markers in response to inductive stimuli compared with ground-state ESCs or Rex1-high cells. They have also gained capacity for PGCLC induction. It has previously been established that responsiveness to germ cell induction cues or factors is not manifest in naive ESCs or the pre-implantation epiblast but is a property acquired during developmental progression ([@bib21], [@bib42]). By transcription factor overexpression, very few BLIMP1/OCT4 double-positive cells could be obtained from the Rex1-high fraction, while the Rex1-low fraction generated them readily. Presumably, mis-expression of germ cell-determining transcription factors interferes with transition of undifferentiated ESCs or 24-hr Rex1-high cells to competence. For cytokine induction of PGCLCs, however, Rex1-high cells are evidently able to transition to a competent state. Slower upregulation of PGCLC markers in Rex1-high cells compared with Rex1-low cells is consistent with this explanation. Thus in the defined ESC system, capacity for PGCLC induction appears to be gained rather rapidly upon loss of Rex1.

NODAL plays pleiotropic roles in the early embryo. Expression can be detected in the inner cell mass and persists throughout the epiblast until axis specification, when it becomes restricted to the proximal posterior region ([@bib14], [@bib37]). NODAL activity relies on pro-protein convertases, FURIN and PACE4, produced by the extra-embryonic ectoderm, which cleave and activate pro-NODAL ([@bib2], [@bib38]). *Nodal-*deficient embryos die by embryonic day 7.5 ([@bib14], [@bib13], [@bib66]). NODAL activity and autoinduction in the early post-implantation epiblast appears necessary to sustain pluripotency ([@bib19], [@bib37]) and is dependent on paracrine provision of convertases by the extra-embryonic tissues ([@bib2]). Mutant embryos show precocious upregulation of neural markers throughout the egg cylinder and fail to form a primitive streak ([@bib7], [@bib10], [@bib31]). *Nodal* mutants also fail to specify the anterior visceral endoderm ([@bib7]), a signaling center essential for the establishment of anterior-posterior polarity. The multiple functions of NODAL, the complex interplay between extra-embryonic tissues and the epiblast, and the potential redundant activity of GDF3 ([@bib11]) have complicated the precise delineation of its roles in pluripotency progression and lineage specification ([@bib49]).

Mouse ESCs express NODAL and exhibit phosphorylated SMAD2/3 ([@bib41], [@bib46]). Inhibition of NODAL signaling enhances SOX1 expression during differentiation ([@bib36], [@bib57]). Our results show that inhibition of NODAL signaling does not affect the acute downregulation of pluripotency factors when ground-state ESCs are released from 2i, in line with previous observations ([@bib57]). Upregulation of early post-implantation markers is also unaffected. However, suppression of NODAL signaling compromises subsequent responses to inductive stimuli for mesoderm and endoderm, and results in precocious upregulation of neural markers. Interestingly, *Nodal* knockout ESCs exhibited a slightly different phenotype from inhibitor-treated cells. Mutant cells that exited the naive state showed reduced induction of both BRACHYURY and SOX1, with poor survival in both conditions. Lineage specification was not completely abolished, however, either because the requirement for NODAL pathway stimulation is not absolute, or possibly due to compensatory activity of GDF3. Both Alk(i)-treated and *Nodal-*mutant cells showed reduced induction of PCGLCs in response to either transcription factors or cytokines.

A key finding in this study is that the requirement for NODAL signaling is not restricted to the lineage priming stage but is apparent during initial transition from the ESC state, while cells are in the reversible Rex1-high condition ([@bib24], [@bib35]). We have proposed that ESCs and naive epiblast cells transit through a formative phase of pluripotency during which they acquire competence for multi-lineage differentiation, including germline determination, prior to lineage priming ([@bib23], [@bib52]). Formative cells are expected to respond to inductive signals rapidly and efficiently, as observed for Rex1-low cells at 24 hr. The molecular process of lineage capacitation remains unclear but is associated with reconfiguration of the transcription factor network, metabolic reprogramming, enhancer remodeling, and widespread epigenome and chromatin modification ([@bib8], [@bib12], [@bib15], [@bib16], [@bib24], [@bib67]). Our findings point to a pivotal role for NODAL signaling in establishing formative pluripotency, in keeping with observations of a requirement for continuous NODAL activity to sustain pluripotency in the early post-implantation epiblast ([@bib37]). Interestingly, SMAD2/3 is reported to be recruited by "master transcription factors" to regulatory loci in a cell type-specific manner ([@bib41]). In addition, a recent study in human ESCs suggested that SMAD2/3 is able to recruit histone methyltransferases to gene promoters ([@bib3]). Therefore, multi-lineage capacitation could depend upon the presence of SMAD2/3 at specific loci in ESCs during the transition from naive pluripotency.

Experimental Procedures {#sec4}
=======================

Mouse ESC Culture and Differentiation {#sec4.1}
-------------------------------------

RGd2 ESCs were derived in 2i/LIF from heterozygous embryos ([@bib24]). The RGd2/*T*:*mKO2* cell line was generated by targeting the endogenous *T* (BRACHYURY) locus with T2A-mKO2. ESCs were routinely maintained on gelatin-coated plates (Sigma, catalog no. 1890) in N2B27 medium (Stem Cells, SCS-SF-NB-02) supplemented with 1 μM PD0325901 and 3 μM Chir99021 (2i) without LIF, and passaged with Accutase (Millipore, SF006) every 2--3 days. For sorting experiments, cells were plated for 24 hr in 2i at 1.5 × 10^4^ cells/cm^2^ before washing once with PBS and changing the medium to N2B27. After 24--26 hr, cells were sorted by flow cytometry according to GFP levels into Rex1-high (highest 15%) and Rex1-low (lowest 15%) populations using a MoFlo sorter (Beckman Coulter). For neural differentiation, cells were plated at 1.0 × 10^4^ cells/cm^2^ on laminin-coated dishes (Sigma-Aldrich, L2020) in N2B27. Medium was changed every other day. For definitive endoderm induction ([@bib40]), 1.5 × 10^4^ cells/cm^2^ were plated in gelatin-coated plates directly in DE1, before switching to DE2 on day 2. DE2 was renewed on days 4 and 5. DE1 comprises batch-tested N2B27, supplemented with 3 μM Chir99021, 20 ng/mL activin A, 10 ng/mL recombinant mouse FGF4 (R&D Systems, 235-F4-025), 1 μg/mL heparin (Sigma-Aldrich, H3393), and 100 nM PI103 (Cayman Chemical, 10009209). DE2 medium is composed of SF5 base (DMEM/F12 \[Life Technologies, 21331-020\], 0.25% N2, 1% B27 without RA \[Life Technologies, 12587-010\], 0.05% BSA \[Life Technologies, 15260-037\], 0.1 mM β-mercaptoethanol \[Life Technologies, 31350-010\], 2 mM L-glutamine \[Life Technologies, 25030-081\]), supplemented with 3 μM Chir99021, 20 ng/mL activin A, 10 ng/mL FGF4, 1 μg/mL heparin, 100 nM PI103, and 20 ng/mL epidermal growth factor (EGF; Preprotech, AF-100-15). Lateral mesoderm differentiation ([@bib44]) was performed by plating 1.2 × 10^4^ cells/cm^2^ cells in collagen-coated plates (BD BioCoat, 354591) in Glasgow's minimum essential medium (GMEM; Sigma-Aldrich, G5154) with 10% batch-tested fetal calf serum (Sigma-Aldrich), 1× non-essential amino acids (NEAA; Life Technologies, 11140-050), 1 mM sodium pyruvate (Life Technologies, 11360-070), and 1 mM L-glutamine.

Activin A (20 ng/mL) and Chir99021 (3 μM) (GSK3(i)) treatment of sorted fractions was carried out on fibronectin-coated plates (Millipore, FC010) at 1.5 × 10^4^ cells/cm^2^. NODAL inhibitor experiments were carried out using A83-01 1 μM (Alk(i), Tocris Bioscience, 2939) with DMSO (1:10,000) as a carrier control.

Colony-forming assays were conducted by plating 100 cells/cm^2^ per well in laminin-coated plates in 2i supplemented with 1,000 U/mL LIF ([@bib59]). After 5 days, cells were stained using an alkaline phosphatase kit (Sigma, 86 R-1KT) and colonies counted.

For transcription factor induction of PGCLCs, the tri-cistronic Ap2g-T2A-Prdm14-P2A-Blimp1 fragment (APB1, a kind gift from Toshihiro Kobayashi and Azim Surani) was cloned into the phCMV^∗^1-cHA-IRES-H2BBFP plasmid. pPyCAG-PBase, pPBCAG-rtTA-IN, and phCMV^∗^1-APB-IRES-H2BBFP were co-transfected into RGd2 cells by TransIT-LT1 followed by G418 selection (400 μg/mL). For PGCLC induction, cells sorted at 24 hr for RGd2 expression were plated at 2,500 cells per well in a 96-well round-bottomed plate ([@bib42]) in the presence or absence of 1 μg/mL doxycycline (Sigma-Aldrich) in GK15 medium (GMEM, 15% KSR \[Sigma-Aldrich\], 1× NEAA, 1 mM sodium pyruvate, 1 mM L-glutamine, 0.1 mM β-mercaptoethanol \[[@bib21]\]). For cytokine induction of PGCLCs, 2,500 cells were plated in GK15 medium supplemented with 1,000 U/mL LIF, 500 ng/mL bone morphogenetic protein 2 (R&D), 100 ng/mL stem cell factor (R&D), and 50 ng/mL EGF. Aggregates were collected on days 2 and 4 for qRT-PCR.

To generate *Nodal* knockout clones, we transfected RGd2 cells with Cas9 and the guide RNAs CCT CTG CTC CTG AGG CCG GT and CAG TGG CTT GGT CTT CAC GG, which target exons 2 and 3, respectively. Single-cell-derived clones were picked after 55 hr of puromycin selection and a further 5 days of culture. Knockout clones were identified by qRT-PCR and cultured in parallel in either 2i or 2i supplemented with 5 ng/mL activin A (rescue). For differentiation studies with rescue cultures, activin A was present for the initial 24 hr until sorting.

Flow Cytometric Analysis of Fluorescent Reporters {#sec4.2}
-------------------------------------------------

Cells were dissociated into a single-cell suspension using Accutase and resuspended in PBS + 5% fetal bovine serum for analysis using an LSR Fortessa Analyzer (BD Biosciences).

Immunohistochemistry {#sec4.3}
--------------------

Samples were fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized, and blocked for 2 hr with block buffer (PBS + 0.03% Triton X-100 + 3% donkey serum). Cells were incubated overnight at 4°C in block buffer with primary antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}). After three washes with PBS + 0.03% Triton X-100, cells were incubated with secondary antibodies (Life Technologies, 1:1,000) and DAPI in blocking buffer for 3 hr in the dark. After three washes with PBS + 0.03% Triton X-100, cells were left in PBS before imaging. Images were acquired using a Leica DMI3000 B inverted microscope and fluorescence in single cells quantified using CellProfiler ([@bib22]). The number of cells was normalized for each independent experiment (e.g., highest density for a given independent experiment = 1).

Immunostaining of Surface Markers for Flow Cytometry {#sec4.4}
----------------------------------------------------

Cells were dissociated with enzyme-free Cell Dissociation Buffer (Life Technologies, 13151-014) at 37°C. Cells were resuspended with staining buffer (PBS + 1% rat serum) and incubated with directly conjugated antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}) for 30 min at 4°C in the dark. After three washes with staining buffer, cells were analyzed on an LSR Fortessa (BD Biosciences). Spherotech beads were used to quantify the number of cells. Undifferentiated ESCs stained with primary and secondary antibodies were used for FACS gating.

Gene Expression Analysis {#sec4.5}
------------------------

RNA isolation from cell populations was performed with an RNAeasy kit (Qiagen). SuperScriptIII (Invitrogen) and oligo(dT) primers were used to synthesize cDNA. TaqMan, UPL, and SybrGreen probes were used ([Table S2](#mmc1){ref-type="supplementary-material"}).

Gene Knockdown {#sec4.6}
--------------

Qiagen FlexiTube siRNAs for *Nodal*, *Tdgf1*, *Smad2*, and *Smad3* at a final concentration of 20 nM were used for gene knockdown. 1.5 × 10^4^ cells/cm^2^ were transfected in 24-well plates containing 500 μL of 2i medium with 0.5 μL of Lipofectamine RNAiMAX (Life Technologies, 13778075). After overnight incubation, cells were washed once with PBS before transfer to N2B27. Efficiency of transfection was quantified by flow cytometry on RGd2 cells transfected overnight with siRNA against GFP. Gene knockdown was quantified by qRT-PCR after overnight transfection.

Immunoblotting {#sec4.7}
--------------

Western blotting was performed using standard techniques. Primary antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}) were detected using peroxidase-conjugated secondary antibodies (Sigma-Aldrich, 1:5,000). Amersham ECL western blotting detection reagent (RPN2106) was used according to the manufacturer\'s instructions.

Statistics {#sec4.8}
----------

ANOVA was used to compare three or more samples. Two-tailed Student\'s t test was used for pairwise comparisons. For all experiments, n ≥ 3.
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